|
DCF -Bewertung der Neuroone Medical Technologies Corporation (NMTC)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NeuroOne Medical Technologies Corporation (NMTC) Bundle
Unabhängig davon, ob Sie ein Investor oder Analyst sind, ist dieser (NMTC) DCF -Taschenrechner Ihr ultimatives Werkzeug für eine genaue Bewertung. Mit den tatsächlichen Daten der Neuroone Medical Technologies Corporation können Sie Prognosen anpassen und die Auswirkungen in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.9 | .2 | .2 | 2.0 | 3.5 | 4.2 | 5.0 | 6.0 | 7.3 | 8.8 |
| Revenue Growth, % | 0 | -90.75 | -3.92 | 1040.65 | 76.86 | 20.55 | 20.55 | 20.55 | 20.55 | 20.55 |
| EBITDA | -4.9 | -9.8 | -9.9 | -11.8 | -11.8 | -4.2 | -5.0 | -6.0 | -7.3 | -8.8 |
| EBITDA, % | -251.98 | -5499.97 | -5790.85 | -602.12 | -342.96 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | .1 | .2 | .2 | .2 | 1.7 | 2.0 | 2.5 | 3.0 | 3.6 |
| Depreciation, % | 3.66 | 82.59 | 132.16 | 10.21 | 7.15 | 40.72 | 40.72 | 40.72 | 40.72 | 40.72 |
| EBIT | -4.9 | -9.9 | -10.1 | -12.0 | -12.1 | -4.2 | -5.0 | -6.0 | -7.3 | -8.8 |
| EBIT, % | -255.65 | -5582.56 | -5923.01 | -612.32 | -350.1 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 4.0 | 6.9 | 11.1 | 5.3 | 1.5 | 3.7 | 4.4 | 5.4 | 6.4 | 7.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .2 | .4 | .5 | .6 | .8 | .9 |
| Account Receivables, % | 0 | 27.13 | 19.42 | 0 | 5.12 | 10.33 | 10.33 | 10.33 | 10.33 | 10.33 |
| Inventories | .0 | .1 | .7 | 1.7 | 2.6 | 2.7 | 3.2 | 3.9 | 4.7 | 5.6 |
| Inventories, % | 0 | 55.17 | 411.6 | 88.44 | 76.31 | 63.98 | 63.98 | 63.98 | 63.98 | 63.98 |
| Accounts Payable | .8 | .5 | .9 | .7 | 1.0 | 2.5 | 3.1 | 3.7 | 4.4 | 5.4 |
| Accounts Payable, % | 39.58 | 296.85 | 541.96 | 35.09 | 29.81 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 |
| Capital Expenditure | -.1 | -.1 | -.3 | -.4 | -.1 | -1.4 | -1.7 | -2.0 | -2.4 | -2.9 |
| Capital Expenditure, % | -6.35 | -37.65 | -160.79 | -19.67 | -3.48 | -33.43 | -33.43 | -33.43 | -33.43 | -33.43 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.9 | -9.9 | -10.1 | -12.0 | -12.1 | -4.2 | -5.0 | -6.0 | -7.3 | -8.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.2 | -10.2 | -10.4 | -13.4 | -12.7 | -2.6 | -4.8 | -5.7 | -6.9 | -8.4 |
| WACC, % | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -21.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -9 | |||||||||
| Terminal Value | -144 | |||||||||
| Present Terminal Value | -98 | |||||||||
| Enterprise Value | -120 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | -119 | |||||||||
| Diluted Shares Outstanding, MM | 27 | |||||||||
| Equity Value Per Share | -4.44 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NMTC financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the impact of your inputs on NeuroOne’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Gain access to precise historical figures and future forecasts tailored for NeuroOne Medical Technologies Corporation (NMTC).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to clearly present your valuation insights.
- Suitable for All Experience Levels: A straightforward design catering to investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file for NeuroOne Medical Technologies Corporation (NMTC).
- Step 2: Review the pre-filled financial data and forecasts specific to NMTC.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment decisions regarding NMTC.
Why Choose This Calculator?
- Accurate Data: Real NeuroOne Medical Technologies Corporation (NMTC) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-built calculations save you the hassle of starting from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the medical technology sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling NeuroOne Medical Technologies Corporation (NMTC) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models tailored for NeuroOne Medical Technologies Corporation (NMTC).
- Consultants: Deliver professional valuation insights about NeuroOne Medical Technologies Corporation (NMTC) to clients quickly and accurately.
- Business Owners: Understand how innovative companies like NeuroOne Medical Technologies Corporation (NMTC) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to NeuroOne Medical Technologies Corporation (NMTC).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled NeuroOne Medical Technologies Corporation (NMTC) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for NeuroOne Medical Technologies Corporation (NMTC).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.